22 reports of this reaction
1.7% of all HYDROQUINONE reports
#15 most reported adverse reaction
SKIN ATROPHY is the #15 most commonly reported adverse reaction for HYDROQUINONE, manufactured by Obagi Cosmeceuticals LLC. There are 22 FDA adverse event reports linking HYDROQUINONE to SKIN ATROPHY. This represents approximately 1.7% of all 1,310 adverse event reports for this drug.
Patients taking HYDROQUINONE who experience skin atrophy should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
SKIN ATROPHY is a less commonly reported adverse event for HYDROQUINONE, but still significant enough to appear in the safety profile.
In addition to skin atrophy, the following adverse reactions have been reported for HYDROQUINONE:
SKIN ATROPHY has been reported as an adverse event in 22 FDA reports for HYDROQUINONE. This does not prove causation, but indicates an association observed in post-market surveillance data.
SKIN ATROPHY accounts for approximately 1.7% of all adverse event reports for HYDROQUINONE, making it a notable side effect.
If you experience skin atrophy while taking HYDROQUINONE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.